Trial Profile
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerabillity of CJ-30060 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Amlodipine/rosuvastatin/valsartan (Primary) ; Amlodipine/valsartan; Rosuvastatin
- Indications Hyperlipidaemia; Hypertension
- Focus Pharmacokinetics
- Sponsors CJ HealthCare; HK inno.N
- 27 Aug 2018 New trial record